VALANX Biotech Achieves Top Ranking at RESI Boston Innovator’s Pitch Challenge
VALANX, a pioneering company in the field of biotechnology, proudly announces its success at the RESI Boston Innovator’s Pitch Challenge 2024. With an impressive average score of 4.8 out of a possible 5, VALANX took a win in its category and secured the ‘Judges Selected Pitch Companies’ stamp of approval.
RESI 2024 event, held in Boston from September 25 th to 27th was organized by Life Science Nation (LSN), and provided a unique platform for early-stage life science companies in biotech, medtech, diagnostics, and digital health to showcase their innovations and connect with leading investors.
The event featured 56 participating companies, grouped into 14 sessions featuring 4 innovative companies aligned by sector or technology.
Each startup was evaluated by a panel of experienced judges for the quality of their pitch, their ability to respond to challenging questions, and the clarity in presenting their value proposition. Only 14 companies, including VALANX, were awarded the ‘Judges Selected Pitch Companies‘ stamp of approval, reflecting their exceptional standing.
VALANX and its innovative site-specific protein conjugation technology was presented by Michael Lukesch, the CEO. “Competing against high-caliber startups, VALANX’s performance at RESI Boston 2024 not only demonstrated its competitive edge but also underscored its commitment to driving innovation in the life sciences,” Lukesch stated.
This achievement solidifies VALANX’s position in the biotechnology sector, poised to make significant advancements in therapeutic applications through precise and reproducible protein conjugation solutions, not only in Europe but worldwide.
“RESI was incredibly useful to promote our cutting-edge technology to investors in the US, a market we are currently building our network in more and more,” said Lukesch, following VALANX’s win.
Facilitating partnerships that accelerate the journey of life-changing treatments to patients is the mission behind Life Science Nation. By bringing together over 350 investors and 350 early-stage companies, RESI Boston supported this mission once again.
“RESI Boston 2024 was a landmark event… With over 2,000 official partnering meetings and hundreds more happening informally, the conference proved to be an invaluable platform for connecting investors and startups.” concluded Karen Deyo, Vice President of Product at LSN.